Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US. The company said the FDA would ...
The Food and Drug Administration has pushed back the release of its decision on approval of Moderna’s respiratory syncytial virus vaccine by up to three weeks due to “administrative ...
The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna ...
What difference does a few weeks make? Moderna will have to consider that after receiving word that the FDA will not meet a May 12 decision date for its respiratory syncytial virus (RSV) vaccine ...
(RTTNews) - Moderna, Inc. (MRNA) announced Friday that the U.S. Food and Drug Administration's review of the Biologics License ...
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for ...
The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA ...
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory syncytial virus due to “administrative constraints ...
Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's respiratory syncytial virus (RSV) vaccine. Just days before its ...